Two South Korean pharmaceutical companies, Hanall Biopharma and Daewoong Pharmaceutical, have announced a strategic investment in Vincere Biosciences, a longevity biotech specializing in mitophagy-based therapeutics for neurodegenerative and other age-related diseases. The investment aims to foster collaborative opportunities in the field of Parkinson’s disease treatment and advance the development of innovative therapies.
Vincere is known for its cutting-edge research and development in neurodegenerative diseases. The new investment will provide the company with substantial financial support and resources to further its research and development activities. The funding infusion will enable Vincere to expedite the discovery of novel drug candidates, conduct preclinical and clinical studies, and pursue regulatory approvals for potential therapies. The size of the investment was not disclosed at this time.
“This partnership highlights the joining of forces across a shared mission to deliver disease-modifying medicines for Parkinson’s disease,” said Dr Spring Behrouz, CEO of Vincere Biosciences. “Daewoong and HanAll’s track record of success in clinical studies and shared strategic alignment complement our team’s deep understanding of the underlying biology. We look forward to a productive relationship that will accelerate the delivery of therapeutics to patients in need.”
Together, the three companies aim to combine their collective knowledge, expertise, and resources to accelerate the development of innovative treatments for Parkinson’s disease.
“By combining efforts and resources, we can accelerate the multi-tiered approach HanAll has undertaken in the Parkinson’s space,”said Dr Almira Chabi, CMO and CDO at HanAll Biopharma. “There is a great deal of synergy that can be found among the programs, and, in addition, there are opportunities for collaborations leveraging Vincere’s versatile AI platform to evolve and transform our approach to drug development.”
Parkinson’s disease is a debilitating neurodegenerative disorder that affects millions of people worldwide. It is characterized by the progressive deterioration of motor functions, including tremors, stiffness, and impaired movement. Currently, treatment options for Parkinson’s disease primarily focus on managing symptoms, and there is an urgent need for novel therapeutic approaches.
“This investment reflects our commitment to strategic collaborations, especially at this pivotal moment of convergence between drug development and artificial intelligence,” said Sean Jeong, CEO of HanAll Biopharma. “With the diverse and complementary research approaches among Vincere, Daewoong, and HanAll, we look forward to finding paths to help Parkinson’s patients.”
“We are very pleased to invest in Vincere Biosciences to accelerate the development of innovative therapeutics for Parkinson’s disease, an area of great focus for us,” said Sengho Jeon, CEO of Daewoong Pharmaceutical.
